Zweig-DiMenna Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Zweig-DiMenna Associates’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-11,000	Closed	-$156K	–	190
2018 Q1	$156K	Buy	+11,000	New	+$163K	0.01%	130
2017 Q1	–	Sell	-16,000	Closed	-$259K	–	258
2016 Q4	$259K	Buy	+16,000	New	+$290K	0.02%	160
2016 Q2	–	Sell	-330,900	Closed	-$5.48M	–	217
2016 Q1	$5.48M	Sell	330,900 -102,350	-24%	-$1.79M	0.48%	61
2015 Q4	$9.39M	Buy	433,250 +405,600	+1,467%	+$7.9M	0.47%	75
2015 Q3	$548K	Sell	27,650 -535,250	-95%	-$16.9M	0.02%	151
2015 Q2	$19.6M	Buy	562,900 +62,900	+13%	+$1.92M	1.08%	34
2015 Q1	$13M	Buy	+500,000	New	+$9.17M	0.54%	73

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Zweig-DiMenna Associates's HZNP Position: Q2 2018 in Review

Zweig-DiMenna Associates sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2018, closing a stake of 11,000 shares — an estimated $156K sold.

Zweig-DiMenna Associates first reported a position in HZNP in Q1 2015 and held it in 7 quarters. The position peaked at $19.6M in Q2 2015. 204 funds tracked by Wall St. Rank hold HZNP as of Q2 2018.

Zweig-DiMenna Associates reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2018 after selling out during the quarter.
Zweig-DiMenna Associates sold 11,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2018, an estimated $156K.
Zweig-DiMenna Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 7 quarters.
Zweig-DiMenna Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $19.6M in Q2 2015.
204 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2018.

Based on Zweig-DiMenna Associates's 13F filing for Q2 2018, filed 1 Aug 2018.